Terms of use for this website: copyright, disclaimer, forward-looking statements and limitation of liability.
Copyright. All content on this website — text, layout, figures, tables, marks and publications (including the Peptide Prime magazine) — is the property of Fennegens, Inc. or its licensors and is protected by copyright. No part may be reproduced, excerpted, mirrored or used commercially without prior written permission.
No medical, diagnostic or investment advice. The information published here is for general information only. It is not medical, diagnostic, dosing or treatment advice, and it is not an offer, solicitation, recommendation or invitation to buy or sell any security or to invest in any company.
Investigational compounds and forward-looking statements. All pipeline programmes are preclinical or at candidate-selection stage and have not been approved by any regulatory authority. Statements about investigational compounds, indications, dosing formats, timelines and market expectations are forward-looking, are subject to research, clinical, regulatory and commercial risk, are not guarantees of future performance and may change without notice.
No warranty; third-party content. Content is provided on an “as is” basis without any express or implied warranty as to accuracy, completeness or timeliness. Third-party content, quoted sources and external links remain the property of their respective owners; we do not control and are not responsible for external content, and reliance on this website is at the reader’s own risk.
Limitation of liability. To the maximum extent permitted by applicable law, Fennegens, Inc., Shanghai Fennegens Biopharmaceutical Co., Ltd. and their affiliates accept no liability for any direct or indirect loss arising from the use of, or reliance on, this website. Information handling is described in Privacy & terms.
